Avacta reports positive Phase 1a/1b data for faridoxorubicin in salivary gland cancer

Avacta Group released updated data from its ongoing Phase 1a/1b trial of faridoxorubicin (AVA6000), reporting a median progression-free survival of 11.4 months in a subset of salivary gland cancer patients, versus historical benchmarks of 6 to 6.7 months.

Detected & updated continuously · Source: Nebula